Overview

* Gyre Q3 revenue up 20% yr/yr, but missed analyst expectations

* Net income for Q3 doubled to $5.9 mln, reflecting cost control

* Full-year revenue guidance revised down due to Etorel rollout delays

Outlook

* Gyre revises full-year revenue guidance to $115-118 mln due to Etorel® rollout delays

* Company expects continued ETUARY® sales growth to offset challenges with Etorel® and Contiva®

* Gyre plans to initiate Phase 2/3 trial for pirfenidone in Q4 2025

Result Drivers

* For the three months ended September 30, 2025, research and development expense was $2.4 million, compared to $2.8 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $30.56 $34 mln

Revenue mln (2

Analysts

)

Q3 Net $5.94

Income mln

Q3 $6.93

Operatin mln

g Profit

Q3 $7.63

Pretax mln

Profit

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)